Safety Evaluation of the Food Enzyme D-Allulose 3-Epimerase from Genetically Modified Escherichia coli

Why this opinion matters

If you formulate with D-allulose, the enzyme behind it matters more than the sweetener’s label. In 2021, the European Food Safety Authority published a safety evaluation for D-allulose 3-epimerase (DAE) produced from a genetically modified Escherichia coli strain. The opinion appears in EFSA Journal 2021;19(3):6565. It gives food formulators and ingredient buyers a clear regulatory reference point for one specific production route.

Background

D-allulose is a rare sugar that tastes like sucrose but delivers fewer calories. It occurs naturally in small amounts, but commercial production depends on enzymatic conversion. DAE catalyzes the conversion of fructose to D-allulose. That makes the enzyme a central processing aid for any supplier selling bulk D-allulose.

This EFSA evaluation focuses on DAE made in a genetically modified E. coli strain. The enzyme is used as an immobilized preparation. That detail matters. The safety conclusion does not cover every DAE product on the market. It covers this enzyme, in this form, for this use.

What EFSA evaluated

The panel looked at the food enzyme as a processing aid in fructose processing. The goal is to produce the specialty carbohydrate D-allulose. The enzyme itself is immobilized, which means it stays in the reactor rather than moving downstream with the sugar stream.

The production process includes purification steps. Those steps remove residual total organic solids. Because of that removal, EFSA did not calculate a dietary exposure value. The panel also did not consider toxicological studies necessary for this enzyme. That is not a routine conclusion. It follows from the purification data and the immobilized nature of the preparation.

The panel’s final conclusion is direct: the food enzyme, when used in immobilized form, raises no safety concern.

Key findings

Aspect	What the EFSA opinion says
Enzyme	D-allulose 3-epimerase
Production organism	Genetically modified Escherichia coli
Physical form	Immobilized preparation
Application	Fructose processing to produce D-allulose
Dietary exposure	Not calculated; purification removes residual total organic solids
Toxicology studies	Not considered necessary
Safety conclusion	No safety concern when used in immobilized form

What this means for manufacturers

Buyers should read this opinion as a piece of the regulatory file, not as a general endorsement of all D-allulose enzymes. The EFSA conclusion is tied to the immobilized form. If a supplier offers a soluble DAE from the same or a similar strain, you cannot automatically apply this opinion to it. The same logic applies to different production organisms.

For formulators, the practical point is simpler. The enzyme does not carry the safety burden in the final D-allulose product. The purification steps remove the enzyme-related solids before the ingredient reaches your syrup. EFSA saw no dietary exposure from the enzyme preparation, which means the finished sweetener is the only thing you need to evaluate for your own label.

That also gives ingredient buyers a useful question to ask suppliers. Does your D-allulose come from an immobilized DAE process with documented removal of total organic solids? If yes, this EFSA opinion supports that route. If the supplier cannot show purification data or uses a soluble enzyme, ask for more evidence.

FAQ

Does this EFSA opinion apply to all D-allulose enzymes?

No. It applies only to DAE produced from the genetically modified E. coli strain described in the application, and only when used in immobilized form.

Why were toxicology studies not performed?

The applied purification steps remove residual total organic solids from the enzyme preparation. Because the enzyme does not end up in the final D-allulose product, EFSA considered dietary exposure negligible and toxicology studies unnecessary.

Can I cite this opinion in a regulatory submission?

Yes. The opinion is published in EFSA Journal as 2021;19(3):6565. You can reference it as part of the safety evidence for D-allulose produced with this immobilized enzyme route.

For a specialty carbohydrate like D-allulose, clean regulatory support matters as much as clean taste. The 2021 EFSA opinion gives formulators and buyers a practical reference point they can actually use.